Publications in collaboration with researchers from Hospital Universitario Nuestra Señora de Candelaria (28)

2024

  1. Assessing illness-related uncertainty in relapsing-remitting multiple sclerosis: A psychometric analysis of the Mishel Uncertainty of Illness Scale

    Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 10, Núm. 2

  2. Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study

    Multiple Sclerosis and Related Disorders, Vol. 90

  3. Decisional Conflict Regarding Disease-Modifying Treatment Choices Among Patients with Mid-Stage Relapsing-Remitting Multiple Sclerosis

    Patient Preference and Adherence , Vol. 18, pp. 1163-1171

  4. Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry

    Neuromuscular Disorders, Vol. 34, pp. 1-8

  5. XVI Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2023 (I)

    Revista de neurologia, Vol. 79, Núm. 1, pp. 21-29

  6. XVI Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2023 (II)

    Revista de neurologia, Vol. 79, Núm. 2, pp. 51-66

2023

  1. Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study

    Neurology and Therapy, Vol. 12, Núm. 6, pp. 2177-2193

  2. Epidemiology of ataxia and hereditary spastic paraplegia in Spain: a cross-sectional study

    Neurologia, Vol. 38, Núm. 6, pp. 379-386

2022

  1. Consensus on early detection of disease progression in patients with multiple sclerosis

    Frontiers in Neurology, Vol. 13

  2. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

  3. Expert-Agreed Practical Recommendations on the Use of Cladribine

    Neurology and Therapy

2020

  1. New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab

    Frontiers in Neurology, Vol. 11

  2. New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy

    Brain, Vol. 143, Núm. 9, pp. 2696-2708

2019

  1. PDGF-BB serum levels are decreased in adult onset Pompe patients

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. A guide to treating gait impairment with prolonged-release fampridine (Fampyra ® ) in patients with multiple sclerosis

    Neurologia

2017

  1. Assessment of plasma chitotriosidase activity, CCL18/PARC concentration and NP-C suspicion index in the diagnosis of Niemann-Pick disease type C: A prospective observational study

    Journal of Translational Medicine, Vol. 15, Núm. 1

  2. Erratum to “Safety, efficacy and outcome-related factors of perampanel over 12months in a real-world setting: The FYDATA study” [Epilepsy Res. (2016) 126 (201–210)] (S0920121116301218)(10.1016/j.eplepsyres.2016.08.001)

    Epilepsy Research

2016

  1. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study

    Epilepsy Research, Vol. 126, pp. 201-210

2015

  1. Consenso español actualizado sobre el uso del natalizumab (Tysabri®)-2013

    Neurologia, Vol. 30, Núm. 5, pp. 302-314

2014

  1. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: Results of the 1-year ESLIBASE retrospective study

    Epilepsy Research, Vol. 108, Núm. 7, pp. 1243-1252